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Prophylactic aprotinin therapy has become a popular method to reduce 
bleeding associated with cardiac operations. Today essentially two dose 
regimens are used, a high-dose regimen with administration throughout the 
complete operative procedure and a low-dose regimen with administration 
only during bypass. In unblinded studies both regimens were found to be 
equally effective. This double-blind placebo-controlled study in 115 patients 
undergoing elective coronary artery bypass grafting was done to confirm 
these results without potential investigator bias. Intraoperative h moglobin 
loss was significantlY reduced (p < 0.0!) by 42% in the high-dose group and 
by 17% in the low-dose group compared with loss in control subjects. Blood 
loss 6 hours after operation was 377 ml in the low-dose and 266 ml in the 
high,dose group compared with 630 ml in the placebo group (p < 0.05 and 
p < 0.001, respectively). The average number of transfusions with packed 
red blood cells was reduced 31% in the lowldose group and 45% in the 
high-dose group, but the reductions were not significant. In a subgroup of 
patients, markers for coagulation and fibrinolysis were studied to investi- 
gate whether a different extent of activation existed. Fibrinolysis as 
measured by D-dimer levels was completely inhibited by the high.dose 
regimen, but was only partly suppressed in the low-dose group as compared 
with findings in the placebo group. Thrombin generation during cardiopul. 
monary bypass as reflected by FI+ 2 levels was lower in patients treated with 
aprotinin, but the difference was not significant. Concentrations of throm, 
bin inactivated by antithrombin I I I  were not different between the groups. 
The observation that low-dose aprotinin significantly improved hemostasis 
but did not inhibit hyperfibrinolysis supports our previous finding that 
low-dose aprotinin mainly protects platelet adhesive function. The better 
result obtained with high-dose aprotinin may indicate the contribution of 
hyperfibrinolysis to bleeding after cardiopulmonary b pass. Because,high- 
dose aprotinin is administered outside the period of full heparinization and 
might therefore increase the risk of thromboembolic complications, we 
propose a modification of the low-dose schedule to increase aprotinin levels 
sufficient for plasmin inhibition before release of the aortic crossclamp. 
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p ostoperative bleeding is a common problem in 
cardiac operations and cardiac surgeons have 
become increasingly aware of the risks associated 
with transfusion of homologous blood products. 
This has prompted a search for methods to improve 
hemostasis in cardiac operations. Of several phar- 
macologic interventions, perioperative treatment 
with the antiprotease aprotinin has gained popular, 
ity in Europe. Initial experience with aprotinin was 
obtained with the 6 million kallikrein inhibiting 
units (KIU), or high-dose, schedule. 1 Numerous 
reports have confirmed its efficacy and safety. 2-4 
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There remain, however, concerns about possible 
thromboembolic side effects and early graft throm- 
bosis with administration of aprotinin outside the 
period of full heparinization. 5-7 To avoid exposure 
of the patient to aprotinin during unheparinized 
periods, Wildevuur and associates s introduced the 2 
million KIU, or low-dose, regimen in which aproti- 
nin is added solely to the pump prime. Results from 
nonblinded studies indicate that the efficacy of both 
regimens is equal. TM This finding has been related 
to the inhibition of the initial effect of cardiopulmo- 
nary bypass (CPB) on platelet hemostatic function, 
which was shown to be the same for both regimens. 9 
The present double-blind placebo-controlled study 
was designed to demonstrate the comparable ffec- 
tiveness of the low- and high-dose schedules in a 
large group of patients. 
In a subgroup of patients we measured F1+2 and 
thrombin-ant ithrombin I I I  (TAT) complex levels as 
markers for thrombin generation and D-dimer lev- 
els as a marker of fibrinolysis to establish whether 
the two aprotinin regimens had different effects on 
these components of the hemostatic balance. 
Patients and methods 
After informed consent was obtained 115 patients 
scheduled for elective coronary artery bypass grafting 
were entered into the study. The study protocol was 
approved by the scientific and ethical committees of our 
hospital. 
The following exclusion criteria for entry to the study 
were used: history of previous cardiac operation, possible 
exposure to aprotinin in the past, allergy or clotting 
disorder, severe cardiac failure (ejection fraction <25%), 
and impaired renal function (serum creatinine level >200 
~mol/L). A large proportion of the patients were treated 
with 80 mg acetylsalicylic acid or 100 mg carbasalate 
calcium daily. These drugs were stopped on the day of 
admission to the hospital. 
Study drug administration. The blinded study medica- 
tion was supplied by Bayer AG (Leverkusen, Germany) in 
boxes containing 12 bottles with 50 ml solution. Eight 
bottles were marked "infus" and four were marked 
"pump." In the placebo group all bottles contained saline 
solution; in the low-dose group only the bottles marked 
"pump" contained 500,000 KIU aprotinin and the remain- 
ing bottles contained placebo; and in the high-dose group 
all bottles contained 500,000 KIU aprotinin. 
The solution from the "infus" bottles was transferred 
into a transfusion bag that was connected to an Ivac 
infusion pump (Ivac Corporation, San Diego, Calif.). The 
infusion was started when the first skin incision was made 
at a rate of 400 ml/hr during 30 minutes to deliver the 
loading dose of 2 million KIU. During the remainder of 
the operation the infusion rate was set at 50 ml/hr 
(500,000 KIU aprotinin/hour). The solution from the 
"pump" bottles was transferred to the priming volume of 
the extracorporeal circuit. The randomization code was 
kept by Bayer AG. The code was broken after data 
acquisition was complete and verified. 
Anesthesia and CPB. Anesthesia comprised premedi- 
cation with lorazepam; induction with sufentanyl, pancu- 
ronium bromide, and etomidate or propofol; and mainte- 
nance with a continuous infusion of sufentanyl. An 
infusion of dopamine and nitroglycerin was routinely 
started at the termination of CPB. 
The extracorporeal circuit contained either a William- 
Harvey HF 5400 (Bard, Tustin, Calif.) or an Avecor 
Ultrox I (Avecor, Plymouth, Minn.) oxygenator primed 
with Ringer's lactate 2000 ml, 20% human albumin 200 
ml, 20% mannitol 100 ml, 8% sodium bicarbonate 50 ml, 
heparin 50 rag, and cefamandole 2 gin. Before cannula- 
tion, heparin (3 mg/kg) was given. Predonation was done 
whenever possible. During bypass an additional 50 mg of 
heparin was given every hour irrespective of the activated 
clotting time (ACT). Heparin was neutralized with prota- 
mine sulfate in a 1:1 ratio with the initial dose. Additional 
dosage of protamine was guided by results of repeat ACT 
tests after the residual volume in the extracorporeal 
circuit was returned to the patient. Flow ranges were from 
2.0 to 2.4 L/m 2 per minute during moderate hypothermia 
(28 ° to 32 ° C). Cardioplegia was achieved with ice-cold 
crystalloid cardioplegic solution infused in the ascending 
aorta after clamping. 
Blood loss, To calculate the intraoperative hemoglobin 
loss all gauzes were weighed, washed with 1 L saline 
solution, and the fluid content sampled for hemoglobin 
concentration. The volume of wasted suction fluid was 
measured and, after vigorous haking, sampled for mea- 
surement of hemoglobin concentration. With these data 
we calculated the intraoperative hemoglobin loss. The 
volume of mediastinally shed blood was measured 6 and 
24 hours after operation. 
Transfusion of blood products. Packed red blood cells 
were given during CPB when the hematocrit value 
dropped below 0.20. After CPB and in the intensive care 
unit (ICU) packed cells were given when the hematocrit 
value decreased to less than 0.25. Fresh frozen plasma 
(FFP) was only given to correct clotting disorders; that is, 
in the operating room FFP was given when there was 
insufficient clotting despite an ACT value that had re- 
turned to the normal range. FFP was given in the ICU 
when there was excessive bleeding and normal activated 
partial thromboplastin time values were present. 
Blood sampling. In 14 patients in each group markers 
for fibrinolysis and coagulation were studied. Blood sam- 
ples were drawn from a central venous line or the 
extracorporeal circuit after induction of anesthesia; 5
minutes after onset of extracorporeal circulation; and 10 
minutes before and 5 minutes after release of the aortic 
crossclamp. The samples were collected in tubes contain- 
ing sodium citrate (final concentration 1.05 mmol/L), 
centrifuged at 3000 rpm for 10 minutes, and the obtained 
plasma stored in aliquots at -20 ° C. 
By enzyme-linked immunosorbent assay techniques the 
concentrations of TAT complex, prothrombin fragment F 
(Behringwerke, Marburg, Germany), and D-dimer (Boelar -~ 
inger-Mannheim, Stago, Desnieres, France) were measured. 
The ratio between the initial hematocrit value and the 
hematocrit value at the sample point was used to correct he 
concentrations for hemodilution. 
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Table I. Patient data 
Group 
Placebo Low-dose High-dose 
No. 37 37 38 
Age (yr) 57 ± 8* 62 ± 9 62 _+ 9 
Male gender (%) 78 89 79 
BSA (m 2) 1.96 + 0.15 1.94 _+ 0.14 1.94 ± 0.14 
Preop. ASA (No.) 23/37 20/38 23/38 
Preop. day ASA 3.0 + 1.9 3.1 ± 1.5 3.0 -+ 1.8 
discontinued 
Distal anastomoses 3.6 _+ 1.1 3.7 ± 1.0 3.7 ± 1.0 
(No.) 
LITA used (%) 59 57 50 
Perfusion time 113 ± 35 111 _+ 29 122 _+ 35 
(rain) 
Crossclamp time 69 +- 22 69 ± 22 75 ± 23 
(rain) 
Data are expressed as mean plus or minus standard eviation. BSA, Body 
surface area; ASA, acetylsalicylic a id; LITA, left internal thoracic artery. 
*p < 0.02 placebo versus 2 million and 6 million KIU. 
Aprotinin concentrations were measured (Dr. Lemm, 
Bayer AG, Wuppertal, Germany) in samples drawn 5 
minutes after the start of CPB and after administration f 
protamine according to the method of Mfiller-Esterl and 
colleagues. 12 
Statistical analysis. Because data of the intraoperative 
and postoperative blood loss were not normally distrib- 
uted a log transformation was done. The differences between 
the groups for these and other continuous data were tested 
with analysis of variance. The Bonferroni-Holm ethod was 
used to correct for the multiple comparisons artifact. The 
data of F1+2, TAT, and D-dimer measurements were tested 
with analysis of variance for repeated measurements. Cate- 
gorical data were tested for statistical significance with the X a 
test. Correlations were calculated with the Spearman rank 
correlation test. A p value less than 0.05 was considered 
significant. All analyses were done with SPSS software (SPSS 
Inc., Chicago, ILL). 
Results 
Patients. One hundred fifteen patients were ran- 
domized. Three patients were excluded: one patient 
from the placebo group in whom concurrent with 
the coronary artery bypass grafting a small left ventric- 
ular aneurysm was resected, another patient from the 
placebo group who had excessive postoperative bleed- 
ing because of a broken suture, and one patient from 
the high-dose group who had dense pericardial adhe- 
sions resembling those found in a reoperation. 
The demographic and operative data of the three 
groups are shown in Table I. The groups did not differ 
except for age, which was significantly lower in the 
placebo group. However, age did not show a correla- 
tion with postoperative blood loss (p > 0.1 in each 
group, Spearman rank correlation), and the difference 
was therefore considered not to be of importance. 
Table II. Blood loss 
Group 
Blood loss Placebo Low-dose High-dose 
Intraoperative 5.2 _+ 3.2 4.3 ± 2.6 3.0 - 2.1" 
(mmol) 
Postoperative (ml) 
6 h 630 ± 637 377 ± 376? 266 _ 204¢ 
24 h 1068 _+ 1047 662 ± 467? 504 + 275¢ 
Data are expressed as mean plus or minus standard eviation. 
*p < 0.01 versus placebo. 
?p < 0.05 versus placebo. 
~p<0.001 versus placebo. 
Blood loss. The intraoperative hemoglobin loss 
was significantly (p < 0.01) reduced in the high-dose 
group, but not in the low-dose group (p = 0.22) 
compared with that in the placebo group (Table II). 
The volume of mediastinal drainage was reduced 
significantly in the low- and high-dose groups com- 
pared with that in the placebo group at 6 and 24 
hours after operation (p < 0.02 and p < 0.05 in the 
low-dose group andp < 0.001 andp < 0.001 in the 
high-dose group, respectively). There were no sig- 
nificant differences in intraoperative and postoper- 
ative blood loss between the low-and high-dose 
groups. 
Hemoglobin and thrombocyte l vels. Except for a 
significantly lower hemoglobin level after induction 
of anesthesia in the high-dose group compared with 
that in the control group (7.8 _ 0.6 versus 8.1 +_ 0.8 
mmol/L) there were no significant differences be- 
tween the hemoglobin and thrombocyte l vels in the 
groups throughout the perioperative and postoper- 
ative periods (data not shown). 
Blood product use. Approximately three quarters 
of the patients received blood products (Table III). 
The reductions in the number of packed cells given 
after the operation in the low- and high-dose groups 
were almost significant (p = 0.07 and 0.08, respec- 
tively). Also, the reductions in FFP transfusion in 
the ICU were almost significant (p = 0.05 for the 
low-dose group and p = 0.09 for the high-dose 
group). The total amount of FFP given periopera- 
tivety was significantly reduced by treatment with 2 
million units aprotinin (p < 0.05). 
D-dimer levels. The D-dimer levels (Fig. 1) were 
at the upper range of normal (<400 /xg/L) in all 
groups before heparinization. In the placebo group 
the D-dimer levels increased further during CPB, 
with a sharp increase after release of the aortic 
crossclamp. In the low-dose group D-dimer levels 
rose moderately during CPB, but increased similarly 
to those in the placebo group after release of the 
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Fig. 1. Plasma levels of D-dimers before and during CPB. Bar represents CPB and triangle indicates 
release of aortic crossclamp. Course in high-dose group was significantly different from course in placebo 
group (p < 0.02, double asterisk). Significant within-group changes are marked with asterisk for placebo 
group, x for low-dose group, and number sign for high-dose group. 
Table III. Blood product use 
Group 
Placebo Low-dose High-dose 
Packed cells (units) 
Intraoperative 1.5 _+ 2.4 1.4 _+ 1.4 1.0 _+ 1.0 
Postoperative 1.4 _+ 2.2 0.6 -+ 1.1 0.6 + 1.0 
FFP (units) 
Intraoperative 0.5 _+ 1.5 0.1 _+ 0.5 0.1 _+ 0.3 
Postoperative 1.3 + 2.3 0.2 _+ 0.6 0.2 _+ 0.6 
No blood products 8/37 (22) 9/37 (24) 11/38 (29) 
(%) 
Data are expressed as mean plus or minus standard deviation. No 
significant differences. 
crossclamp. Treatment with high-dose aprotinin re- 
sulted in complete inhibition of D-dimer formation. 
The course of the D-dimer levels differed signifi- 
cantly between the placebo and high-dose groups 
(p < 0.02) but not between the low- and high-dose 
groups (p = 0.18) and the low-dose and placebo 
groups (p = 0.18). 
TAT levels. TAT levels were already increased 
higher than normal values (1.0 to 4.1 /zg/L) after 
induction of anesthesia nd increased further after 
onset of CPB (Fig. 2). During CPB TAT levels 
decreased, but the levels increased again after re- 
lease of the aortic crossclamp. The time-related 
increase was significant (p < 0.0001) in all groups 
but no significant differences between the groups 
were present. 
F I+ 2 levels. In all groups essentially the same 
course was seen (Fig. 3). The initial values of FI+ 2 
were at the upper range or higher than normal (0.3 
to 1.6 nmol/L) and increased further after initiation 
of CPB. Until release of the aortic crossclamp the 
FI+ 2 levels remained stable. A second increase 
occurred after release of the crossclamp. The time- 
related increase was significant (p < 0.0001) in all 
groups. During operation the FI+ 2 levels in the 
aprotinin groups were lower than the levels in the 
placebo group, but this did not reach statistical 
significance (p = 0.09, placebo versus low-dose, and 
p -- 0.11, placebo versus high-dose). 
Aprotinin levels. Average aprotinin levels after the 
start of CPB were 250 _+ 65 KIU/ml in the low-dose 
group and 405 _+ 115 KIU in the high-dose group. 
After protamine administration the aprotinin levels 
were decreased to 72 ___ 26 KIU/ml and 210 _+ 50 
KIU/ml, respectively. The aprotinin levels at both 
times were inversely correlated with the D-dimer levels 
before and after crossclamp release (p < 0.05, Spear- 
man rank correlation), but not with FI+ 2 and TAT 
levels and intraoperative and postoperative blood loss. 
Clinical performance. No significant differences 
were found in duration of artificial ventilation 
(mean 20 hours) or ICU stay (mean 1.2 days). 
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Fig. 2. Perioperative levels of TAT complex. Levels increased significantly in all groups {p < 0.0001), but 
did not differ between groups. Within-group differences are marked as in Fig. 1. 
Perioperative diuresis and fluid balances did not 
differ significantly between the groups. Creatinine 
levels were slightly increased in all groups at the 
fourth postoperative day compared with the preop- 
erative values, but not significantly. Renal failure 
was not observed in any patient. Perioperative myo- 
cardial infarction was seen in five patients in the 
placebo group, one patient in the low-dose group, 
and four patients in the high dose group (p = 0.40). 
In four patients (4%; three from the placebo 
group and one from the low-dose group), a retho- 
racotomy was done because of bleeding. In three 
patients, one from the placebo group and two from 
the high-dose group, a rethoracotomy was done 
because of myocardial ischemia. Two of these pa- 
tients received an additional venous graft to a vessel 
that was already grafted with a thoracic artery. At 
inspection the left internal thoracic artery anasto- 
moses were patent and there was free flow from these 
grafts, precluding raft thrombosis as the cause for 
the ischemia. Two patients, one from the placebo 
and one from the high-dose group, required post- 
operative support with an intra-aortic balloon pump. 
No other major complications or mortality oc- 
curred. 
Discuss ion 
In this large double-blind trial of aprotinin in 
elective coronary artery bypass grafting both low- 
dose (2 million KIU) and high-dose (6 million KIU) 
aprotinin improved hemostasis, but less intraopera- 
tive bleeding was seen with the high-dose schedule. 
In our previous tudies we showed that the bulk of 
hemoglobin loss occurs during the operative proce- 
dure and that postoperative hemoglobin loss ac- 
counts for just one quarter to one third of the total 
hemoglobin loss. 13 Therefore the better efficacy of 
high-dose aprotinin in this series is reflected by the 
greater reductions in intraoperative hemoglobin 
loss, that is, 17% in the low-dose group and 42% in 
the high-dose group. 
The high-dose schedule was initially engineered 
to obtain a continuous high plasma concentration f 
aprotinin that would inhibit complement activation 
through kallikrein formation during CPB and con- 
sequently reduce the whole body inflammatory e- 
action. 1Because the results of this first study indi- 
cated that aprotinin had no effect on complement 
activation but substantially improved hemostasis, 
various mechanisms have been proposed to explain 
the hemostatic efficacy of aprotinin in cardiac oper- 
ations: inhibition of hyperfibrinolysis, 14' 15 inhibition 
of intrinsic coagulation, 16 preservation of platelet 
adhesive capacity, 1' 17, 18 modulation of endothelial 
eicosanoid synthesis, 19and protection of platelets 
from inhibition by heparin. 2° The rationale to deter- 
mine the mechanism involved is that the adminis- 
tration of aprotinin could then be rationally tailored 
5 2 8 Speekenbrink etal. 
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Fig. 3. Perioperative l vels of prothrombin fragment FI+ 2. Levels increased significantly in all groups 
(p < 0.0001), but did not differ between groups. Within-group differences are marked as in Fig. 1. 
to obtain an optimal efficacy with a low risk of side 
effects. 
Considering hyperfibrinolysis as the main factor 
of impaired hemostasis, Royston al advocated in- 
creasing the initially recommended dose of aproti- 
nin. Wildevuur and associates, 8 on the other hand, 
recommended tailoring the dose of aprotinin to 
preserve primarily the platelet adhesive function by 
giving only a 2 million KIU pump prime dose. In a 
subpopulation of our study group we examined the 
effect of low- and high-dose aprotinin on the activity 
of the coagulation and fibrinolytic systems. Coagu- 
lation activity as reflected by FI+2 and TAT com- 
plexes increased significantly during CPB, with 
marked increases after the start of CPB and after 
release of the aortic crossclamp. FI+ 2 levels were 
lower during operation in the aprotinin-treated 
groups, but the difference did not reach statistical 
significance. Fibrinolytic activity, as reflected by 
D-dimer levels, which increased slowly during by- 
pass and increased sharply after release of the aortic 
crossclamp, correlated inversely with the plasma 
concentrations of aprotinin and was only signifi- 
cantly inhibited by the high-dose regimen. These 
data do indeed support our previous conclusion that 
the 2 million KIU pump prime dose of aprotinin 
improves hemostasis mainly by preservation of the 
platelet adhesive function. &9 
However, the better esult in hemostasis obtained 
with the high-dose regimen suggests that the hyper- 
fibrinolysis observed after release of the aortic cross- 
clamp might play an additional role. This hyperfi- 
brinolysis could be caused by several factors that 
coincide with the release of the aortic crossclamp. 
First, normothermia s restored, resulting in normal 
antiprotease activity that is inhibited during hypo- 
thermia, zz Cardiotomy suction is used more in- 
tensely and returns coagulation- and fibrinolysis- 
activated blood from the pericardial cavity, which 
results in systemic activation of the fibrinolytic sys- 
temY Reperfusion of the ischemic heart and lungs 
might be responsible for the increased tissue plas- 
minogen activator activity observed in this period. 1
Moreover, a peak release of endotoxin (a potent 
stimulus for tissue plasminogen activator elease), 
likely to be trapped in the thoracic duct during 
ventilatory arrest, appears in the systemic ircula- 
tion. 24 Whatever the cause of the hyperfibrinolysis 
might be, complete inhibition by high-dose aprotinin 
but not by the low-dose regimen suggests that 
hyperfibrinolysis  a contributing factor in blood 
loss in cardiac operations. Improved hemostasis 
obtained with drugs that specifically inhibit fibrino- 
lysis, such as e-aminocaproic acid and tranexamic 
acid, confirms the contribution of fibrinolysis to the 
disturbed hemostasis n cardiac operationsY' 26 
The mechanism of protection of the platelet 
adhesive function by aprotinin is still unclear. Many 
authors have suggested a primary role for plasmin in 
the reduced expression of the adhesive glycoprotein 
Ib receptors. TM17, 18 However, as our results show, 
fibrinolysis increases primarily after release of the 
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aortic crossclamp whereas the reduced glycoprotein 
Ib expression was already observed at the beginning 
of bypass, '9 Moreover, low- and high-dose aproti- 
nin were shown to be equally effective in preserving 
glycoprotein Ib expression, 9 but do not equally 
inhibit plasmin activity. The limited role of fibrino- 
lysis is further evidenced by the observation that 
aprotinin also protects platelet function in simulated 
(in vitro) CPB in which plasmin concentrations do 
not increase because of the absence of endothelium- 
derived plasminogen activators. 27 These observa- 
tions make a primary role of plasmin in damage to 
platelet function during CPB doubtful. 
Another suggested mechanism of damage to 
platelet adhesive function during CPB is by throm- 
bin generated through the intrinsic pathway on the 
surface of the extracorporeal circuit. 16'28 In the 
current study thrombin generation was measured 
with the markers F~+ 2 and TAT complex. A typical 
pattern was seen with increased thrombin activity 
after the onset of bypass and after release of the 
aortic crossclamp. This latter event coincides with 
increased cardiotomy suction. Tabuchi and associ- 
ates 23 have observed that coagulation and fibrinoly- 
sis are activated in the pericardial cavity. Evidently 
this activation has to be explained by extrinsic activa- 
tion. Because there is no indication that aprotinin has 
any effect on the extrinsic pathway this would explain 
the similar FI+ 2 and TAT levels in the groups. 
The question is, however, whether small amounts 
of thrombin generated through the intrinsic path- 
way, which is inhibited by aprotinin, 24 can be distin- 
guished in these measurements. Amplification of 
the activation of coagulation by factors V and VIII 
occurs on the phospholipid membranes of platelets. 
In case of extrinsic pathway activation this takes 
place locally in the platelet plug. With intrinsic 
pathway activation on the surface of the extracorpo- 
real circuit, however, adjacent circulating platelets 
will provide the phospholipid surface to amplify 
thrombin generation. In these circumstances, even 
when only a small amount of thrombin is generated, 
a large proportion of the circulating platelets, which 
have a higher affinity for thrombin than fibrinogen, 29 
can be affected by the generated thrombin. It re- 
mains questionable whether this small amount of 
thrombin generated, but with large consequences, 
can be distinguished against the background of 
extrinsically generated thrombin. Possibly this 
amount of intrinsically generated thrombin is re- 
flected by the difference between the FI+ 2 levels in 
the aprotinin-treated groups and the placebo group. 
Since the introduction of aprotinin many authors 
have expressed their fear of an increased prevalence 
of thromboembolic complications and graft throm- 
bosis and reduced graft patency with the use of 
aprotinin as a result of an altered balance between 
thrombosis and fibrinolysis. 5'7, 9 When the 2 million 
KIU schedule is used patients are likely to be 
protected from these complications inasmuch as it is 
administered only during bypass and full hepariniza- 
tion. With the 6 million KIU schedule, however, 
aprotinin is administered before and after bypass 
when there is no protective ffect of heparin, but the 
clotting cascade is being activated because of intra- 
vascular lines, surgical trauma, de-endothelialized 
grafts, and suture materials. This might result in a 
hypercoagulable state in which thrombin production 
is unimpaired, but fibrinolysis is inhibited. 6 More- 
over, aprotinin inhibits activated protein C, a natu- 
ral anticoagulant that, after activation by thrombin, 
inhibits coagulation and promotes fibrinolysis. 5'3o 
The inhibition of this negative feedback mechanism 
of thrombin generation is likely to further increase 
the risk of clot formation. These factors, together 
with the unreliable ACT measurement, 31 make 
aprotinin a potentially dangerous drug. 
The fear of reduced graft patencies or increased 
infarction rate has not been validated in follow-up 
studies.7, 10 On the other hand, in a recent study an 
increased prevalence of graft thrombosis was re- 
ported, 32 possibly caused by an inadequate hepa- 
rinization protocol. Moreover, thrombus formation 
on pulmonary artery lines during aprotinin treat- 
ment has been observed, 33and a study in a porcine 
model of arterial thrombosis howed an increased 
prevalence of arterial occlusion with aprotinin treat- 
ment. 34 To minimize the potential risk of these 
serious complications we believe aprotinin should 
not be administered when full heparinization is not 
in effect. 
However, our results show that the low-dose 
regimen is less effective in blood loss reduction than 
the high-dose regimen and that this might be be- 
cause of insufficient inhibition of hyperfibrinolysis 
after release of the aortic crossclamp. Thus it would 
be logical to increase the aprotinin levels by a 
second dose before release of the crossclamp. On 
the basis of the aprotinin levels in the low-dose 
group a single dose of 1 million KIU before release 
of the crossclamp can be expected to increase the 
levels to exceed 200 KIU/ml, which is sufficient for 
inhibition of plasmin. 1 With this modification the 
low-dose regimen is tailored to protect platelet 
adhesive function at the initial phase of CPB and to 
prevent the hyperfibrinolysis after release of the 
5 3 0 Speekenbrink etal. 
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aortic crossclamp, while avoiding administration of 
aprotinin before heparinization and after neutraliza- 
tion of heparin. 
We are indebted to R. J. Berckmans and M. C. L. 
Schaap for their skillful performance of laboratory assays 
and to J. J. P. Nauta, MSc, for his statistical advice. 
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